Syncona CEO On Why Its 10th Start-Up Focuses On T-Regulatory Cell Therapies
Executive Summary
UK investment group Syncona Ltd has financed its tenth start-up, Quell Therapeutics, with the aim of developing engineered T regulatory (Treg) cell therapies.
You may also be interested in...
Finance Watch: Big Bucks For T-regs In Autoimmune Diseases, Inflammation
GentiBio closed a $157m series A venture capital round, while clinical trial innovator Reify Health raised a $220m series C and Neurelis secured $150m. Also, IPOs slowed in August, but Adagio and Eliem grossed $309.4m and $80m, respectively, and RNA firm Greenlight will go public in a $282m SPAC deal.
UK Firms Big And Small Benefit From Biotech Bubble
Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.
Syncona Focuses On Creating Commercially Ambitious Businesses
With £1bn under management, patient capital company Syncona Limited reveals its strategy for creating and building companies that will generate reimbursable products for patients.